The future of endothelin-receptor antagonism as treatment for systemic hypertension

Current Hypertension Reports

Volumn 8, Issue 1, 2006, Pages 35-44

  Vorobiof, Gabriel ^b   Blaxall, Burns C ^b   Bisognano, John D ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; ANTIHYPERTENSIVE AGENT; ATRASENTAN; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYCLOSPORIN A; DAGLUTRIL; DARUSENTAN; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PHOSPHORAMIDON; PLACEBO; PROSTACYCLIN DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; RENIN; SILDENAFIL; SITAXSENTAN; TEZOSENTAN;

ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DRUG FATALITY; DRUG MECHANISM; ENDOTHELIUM CELL; ESSENTIAL HYPERTENSION; FUTUROLOGY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIVER DYSFUNCTION; LIVER TOXICITY; MUSCLE HYPERTROPHY; NEGRO; NEPHROTOXICITY; NONHUMAN; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; PREECLAMPSIA; PROTEIN FUNCTION; PROTEIN SECRETION; PULMONARY HYPERTENSION; REVIEW; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; RECEPTORS, ENDOTHELIN; TREATMENT OUTCOME; VASOCONSTRICTION;

EID: 33646021907     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-006-0039-2     Document Type: Review

References (99)

1. Hickey KA, Rubanyi G, Paul RJ, et al.: Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 1985, 248:C550-C556.
2. Inoue A, Yanagisawa M, Kimura S, et al.: The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 1989, 86:2863-2867.
3. Kennedy RL, Haynes WG, Webb DJ: Endothelins as regulators of growth and function in endocrine tissues. Clin Endocrinol (Oxf) 1993, 39:259-265.
4. Haynes WG, Webb DJ: Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 1998, 16:1081-1098.
5. Abassi ZA, Tate JE, Golomb E, et al.: Role of neutral endopeptidase in the metabolism of endothelin. Hypertension 1992, 20:89-95.
6. Remuzzi G, Perico N, Benigni A: New therapeutics that antagonize endothelin: promises and frustrations. Nat Rev Drug Discov 2002, 1:986-1001.
7. Haynes WG, Ferro CJ, O'Kane KP, et al.: Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996, 93:1860-1870.
8. Wilkins FC, Alberola A, Mizelle HL, et al.: Chronic pathophysiological circulating endothelin levels produce hypertension in conscious dogs. J Cardiovasc Pharmacol 1993, 22:S325-S327.
9. Rabelink TJ, Kaasjager KA, Boer P, et al.: Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int 1994, 46:376-381.
10. Li JS, Lariviere R, Schiffrin EL, et al.: Effect of a non-selective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats: evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994, 24:183-188.
11. Karam H, Heudes D, Hess P, et al.: Respective role of humoral factors and blood pressure in cardiac remodeling of DOCA hypertensive rats. Cardiovasc Res 1996, 31:287-295.
12. Matsumura Y, Hashimoto N, Taira S, et al.: Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats. Hypertension 1999, 33:759-765.
13. Pollock DM, Derebail VK, Yamamoto T, et al.: Combined effects of AT(1) and ET(A) receptor antagonists, candesartan, and A-127722 in DOCA-salt hypertensive rats. Gen Pharmacol 2000, 34:337-342.
14. Park JB, Schiffrin EL: ETA receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 2001, 37:1444-1449.
15. Barton M, d'Uscio LV, Shaw S, et al.: ETA-receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension 1998, 31:499-504.
16. d'Uscio L, Barton M, Shaw S, et al.: Structure and function of small arteries in salt-induced hypertension: effects of chronic ETA-receptor blockade. Hypertension 1997, 30:905-911.
17. Kassab S, Miller MT, Novak J, et al.: Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertension 1998, 31:397-402.
18. Blezer ELA, Nicolay K, Goldschmeding R, et al.: Early, but not late-onset, endothelin-A receptor blockade can modulate hypertension, cerebral edema and proteinuria in stroke-prone hypertensive rats. Hypertension 1999, 33:137-144.
19. Chillon J-M, Heistad DD, Baumbach GL: Effects of endothelin receptor inhibition on cerebral arterioles in hypertensive rats. Hypertension 1996, 27:794-798.
20. Touyz RM, Turgeon A, Schiffrin EL: Endothelin-A receptor blockade improves renal function and doubles the lifespan of stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 2000, 36:S300-S304.
21. Herizi A, Jover B, Bouriquet N, et al.: Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension 1998, 31:10-14.
22. Li J-S, Schiffrin EL: Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension 1995, 25:495-500.
23. Karam H, Heudes D, Bruvenal P, et al.: Endothelin antagonism in end-organ damage of spontaneously hypertensive rats. Comparison with angiotensin-converting enzyme inhibition and calcium antagonism. Hypertension 1996, 28:379-385.
24. Schiffrin EL, Turgeon A, Deng LY: Effects of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats. Br J Pharmacol 1997, 121:935-940.
25. Rubanyi GM, Polokoff MA: Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994, 46:325-415.
26. Mortensen LH, Fink ED: Captopril prevents chronic hypertension produced by infusion of endothelin-1 in rats. Hypertension 1992, 19:676-680.
27. Falloon BJ, Heagerty AM: In vitro perfusion studies of human resistance artery function in essential hypertension. Hypertension 1994, 24:16-23.
28. Rizzoni D, Porteri E, Guefi D, et al.: Cellular hypertrophy in subcutaneous small arteries of patients with renovascular hypertension. Hypertension 2000, 35:931-935.
29. Dao HH, Moreau P: Endothelin receptor antagonists: novel agents for the treatment of hypertension. Exp Opin Invest Drugs 1999, 8:1807-1821.
30. Schiffrin EL: Role of endothelin-1 in hypertension and vascular disease. Am J Hypertension 2001, 14:83S-89S.
31. Dao HH, Lemay J, de Champlain J, et al.: Norepineprhine-induced aortic hyperplasia and extracellular matrix deposition is endothelin-dependent. J Hypertension 2001, 19:1965-1973.
32. Karam H, Heudes D, Bruvenal P, et al.: Endothelin antagonism in end-organ damage of spontaneously hypertensive rats. Comparison with angiotensin-converting enzyme inhibition and calcium antagonism. Hypertension 1996, 28:379-385.
33. Matsumura Y, Hashimoto N, Taira S, et al.: Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats. Hypertension 1999, 33:759-765.
34. Ammarguellat F, Larouche II, Schiffrin EL: Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin ETA receptor antagonism. Circulation 2001, 103:319-324.
35. Nguyen QT, Cernacek P, Sirois MG, et al.: Long-term effects of nonselective endothelin A and B receptor antagonism in postinfarction rat: importance of timing. Circulation 2001, 104:2075-2081.
36. Galie N, Manes A, Branzi A: The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004, 61:227-237.
37. Channick RN, Simonneau G, Sitbon O, et al.: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001, 358:1119-1123.
38. Rubin LJ, Badesch DB, Barst RJ, et al.: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903.
39. Galie N, Hinderliter AL, Torbicki A, et al.: Effects of the oral endothelin receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003, 41:1380-1386.
40. Barst RJ, Rich S, Widlizt A, et al.: Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002, 121:1860-1868.
41. Barst RJ, Langleben D, Frost A, et al.: Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004, 169:441-447.
42. Barst R: Preliminary results presented at the American Thoracic Society. San Diego, CA: American Thoracic Scoiety; May 2005.
43. Fattinger K, Funk C, Pantze M, et al.: The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001, 69:223-231.
44. Rubin L: Preliminary results presented by at the American Thoracic Society. Orlando, FL: American Thoracic Society; May 2004.
45. ARIES: Ambrisentan in Patients with Moderate to Severe Pulmonary Arterial Hypertension (PAH): http://www.clinicaltrials.gov/ct/show/NCT00091598. Accessed on 6/20/05.
46. Schiffrin EL: Role of endothelin-1 in hypertension and vascular disease. Am J Hypertension 2001, 14:83S-89S.
47. Krum H, Viskoper RJ, Lacourciere Y, et al.: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998, 338:784-790.
48. Nakov R, Pfarr E, Eberle S: Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. For the HEAT Investigators. Am J Hypertens 2002, 15:583-589.
49. Spence S, Anderson C, Cukierski M, et al.: Teratogenic effects of the endothelin receptor antagonist L-753,037 in the rat. Reprod Toxicol 1999, 13:15-29.
50. Myogen Reports Positive Results for Darusentan Phase 2b Trial in Resistant Hypertension. Released on August 18th, 2005. Accessed at www.myogen.com
51. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
52. Saito I, Mizuno K, Niimura S: Urinary endothelin and sodium excretion in essential hypertension. Nephron 1993, 65:152-153.
53. Malatino LS, Bellanuova I, Cataliotti A, et al.: Renal endothelin-1 is linked to changes in urinary salt and volume in essential hypertension. J Nephrol 2000, 13:178-184.
54. Hasdai D, Lerman A: The atherogenic potential of endothelin. Coron Artery Dis 1995, 6:901-904.
55. Lerman A, Edwards BS, Hallet JW, et al.: Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991, 325:997-1001.
56. Ergul A: Hypertension in black patients: an emerging role of the endohelin system in salt-sensitive hypertension. Hypertension 2000, 36:62-67.
57. Elijovich F, Laffer CL, Amador B, et al.: Regulation of plasma endothelin by salt in salt-sensitive hypertension. Circulation 2001, 103:263-268.
58. Elijovich F, Laffer CL, Schiffrin EL, et al.: Endothelin-aldosterone interaction and proteinuria in low-renin hypertension. J Hypertens 2004, 22:573-582.
59. Campia U, Cardillo C, Panza JA: Ethnic differences in the vasoconstrictor activity of endogenous endothelin-1 in hypertensive patients. Circulation 2004, 109:3191-3195.
60. FDA Approves BiDil Heart Failure Drug for Black Patients. http://www.fda.gov/bbs/topics/NEWS/2005/NEW01190.html. Accessed on June 27, 2005.
61. Lariviere R, Thibault G, Schiffrin EL: Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensives but not in spontaneously hypertensive rats. Hypertension 1993, 21:294-300.
62. Abassi ZA, Tate JE, Golomb E: Role of neutral endopeptidase in the metabolism of endothelin. Hypertension 1992, 20:89-95.
63. Malatino LS, Bellanuova I, Cataliotti A, et al.: Renal endothelin-1 is linked to changes in urinary salt and volume in essential hypertension. Salt Sensitivity Group of the Italian Society of Hypertension. J Nephrol 2000, 13:178-184.
64. Hwang YS, Hsieh TJ, Lee YJ, et al.: Circadian rhythm of urinary endothelin-1 excretion in mild hypertensive patients. Am J Hypertens 1998, 11:1344-1351.
65. Elijovich F, Laffer CL: Participation of renal and circulating endothelin in salt-sensitive hypertension. J Hum Hypertens 2002, 16:459-467.
66. Barton M, Carmona R, Ortmann, et al.: Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. Int J Biochem Cell Biol 2003, 35:826-837.
67. Glowinska B, Urban M, Hryniewicz A: Endothelin-1 plasma concentration in children and adolescents with atherogenic risk factors. Kardiol Pal 2004, 61:329-338.
68. Pontiroli AE, Pizzocri P, Koprivec D, et al.: Body weight and glucose metabolism have a different effect on circulating levels of ICAM-1, E-selectin, and endothelin-1 in humans. Eur J Endocrinol 2004, 150:195-200.
69. Mather KJ, Lteif A, Steinberg HO, et al.: Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes 2004, 53:2060-2066.
70. Wheatcroft SB, Williams IL, Shah AM: Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med 2003, 20:255-268.
71. Stjernquist M, Bodelsson G, Poulsen H: Vasoactive peptides and uterine vessels. Gynecol Endocrinol 1995, 9:165-176.
72. Ariza AC, Bobadilla N, Fernandez C, et al.: Effects of magnesium sulfate on lipid peroxidation and blood pressure regulators in preeclampsia. Clin Biochem 2005, 38:128-133.
73. Alexander BT, Rinewalt AT, Cockrell KL, et al.: Endothelin type A receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension 2001, 37:485-9.
74. Wolff K, Kublickiene KR, Kublickas M, et al.: Effects of endothelin-1 and the ETA receptor antagonist BQ-123 on resistance arteries from normal pregnant and preeclamptic women. Acta Obstet Gynecol Scand 1996, 75:432-438.
75. Lowe DT: Nitric oxide dysfunction in the pathophysiology of preeclampsia. Nitric Oxide 2000, 4:441-458.
76. Sagsoz N, Kucukozkan T: The effect of treatment on endothelin-1 concentration and mean arterial pressure in preeclampsia and eclampsia. Hypertens Pregnancy 2003, 22:185-191.
77. Clavell AL, Burnett JC: Physiologic and pathophysiologic roles of endothelin in the kidney. Curr Opin Nephrol Hypertens 1994, 3:66-72.
78. Lariviere R, Lebel M: Endothelin-1 in chronic renal failure and hypertension. Can J Physiol Pharmacol 2003, 81:607-621.
79. Noris M, Remuzzi G: Physiology and pathophysiology of nitric oxide in chronic renal disease. Proc Assoc Am Physicians 1999, 111:602-610.
80. Nabokov AV, Amann K, Wessels S, et al.: Endothelin receptor antagonists influence cardiovascular morphology in uremic rats. Kidney Int 1999, 55:512-519.
81. Brochu E, Lacasse S, Moreau C, et al.: Endothelin ET(A) receptor blockade prevents the progression of renal failure and hypertension in uraemic rats. Nephrol Dial Transplant 1999, 14:1881-1888.
82. Shimizu T, Hata S, Kuroda T, et al.: Different roles of two types of endothelin receptors in partial ablation-induced chronic renal failure in rats. Eur J Pharmacol 1999, 381:39-49.
83. Wang A, Holcslaw T, Bashore TM, et al.: Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 2000, 57:1675-1680.
84. Dupuis J, Goresky CA, Fournier A: Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 1996, 81:1510-1515.
85. Trenkner J, Priem F, Bauer C, et al.: Endothelin receptor A blockade reduces proteinuria and vascular hypertrophy in spontaneously hypertensive rats on high-salt diet in a blood-pressure-independent manner. Clin Sci (Lond) 2002, 103(Suppl 48):385S-388S.
86. Goddard J, Johnston NR, Hand MF, et al.: Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004, 109:1186-1193.
87. Levey AS, Beto JA, Coronado BE, et al.: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998, 32:853-906.
88. Grieff M, Loertscher R, Shohaib SA, et al.: Cyclosporine-induced elevation in circulating endothelin-1 in patients with solid-organ transplants. Transplantation 1993, 56:880-884.
89. Haug C, Duell T, Voisard R, et al.: Cyclosporine A stimulates endothelin release. J Cardiovasc Pharmacol 1995, 26(Suppl3):S239-S241.
90. Bartholomeusz B, Hardy KJ, Nelson AS, et al.: Bosentan ameliorates cyclosporin A-induced hypertension in rats and primates. Hypertension 1996, 27:1341-1345.
91. Kandoussi A, Martin F, Hazzan M, et al.: HMG-CoA reductase inhibition and PPAR-alpha activation both inhibit cyclosporin A induced endotbelin-1 secretion in cultured endothelial cells. Clin Sci (Lond) 2002, 103 (Suppl48):81S-83S.
92. Mraiche F, Cena J, Das D, et al.: Effects of statins on vascular function of endothelin-1. Br J Pharmacol 2005, 144:715-726.
93. Radermacher J, Koch KM: Treatment of renal anemia by erythropoietin substitution: the effects on the cardiovascular system. Clin Nephrol 1995, 44(Suppl1):S56-S60.
94. Brochu E, Lacasse S, Lariviere R, et al.: Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure. J Am Soc Nephrol 1999, 10:1440-1446.
95. Saarelainen S, Seppala E, Laasonen KC, et al.: Circulating endothelin-1 in obstructive sleep apnea. Endothelium 1997, 5:115-118.
96. Grimpen F, Kanne P, Schulz E, et al.: Endothelin-1 plasma levels are not elevated in patients with obstructive sleep apnoea. Eur Respir J 2000, 15:320-325.
97. Quan SF, Gersh BJ: Cardiovascular consequences of sleep-disordered breathing: past, present and future: report of a workshop from the National Center on Sleep Disorders Research and the National Heart, Lung, and Blood Institute. Circulation 2004, 109:951-957.
98. Phillips BC, Narkiewicz K, Pesek CA, et al.: Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens 1999, 17:61-66.
99. Lohmeier T, Barrett A, Irwin E: Prolonged activation of the baroreflex: a viable approach for the treatment of hypertension. Curr Hypertens Rep 2005, 7:193-198.